Low blood cell count is a known complication during cancer treatment.1,2 The European Cancer Anemia Survey (ECAS) evaluated the prevalence, incidence, and treatment of anemia in cancer patients.3 Data from 15,367 patients included tumor type, performance status, hemoglobin (Hb) levels, and cancer treatments. The gene discussed is GSTM1; the disease is anemia (phenotype).